Active, Not Recruiting
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
NCT03341936
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +7 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States